Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X842 dose-finding study in refractory erosive reflux esophagitis
2020-003319-91Phase 2Completed
- Sponsor
- Cinclus Pharma
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) comparing X842 arm with Lansoprazole active comparator arm (2 arms). Primary endpoint: Healing of erosive esophagitis after 4 weeks. Started Dec 2020; status: completed.
02
Drugs
linaprazan gluratelansoprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2020-003319-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003319-91.